Please wait while we load the requested 10-Q report or click the link below:
For Investors: Rebecca Peterson, (781) 609-6378
For Media: Jennifer Snyder, (781) 609-6166
Record Sales of RISPERDAL®CONSTA®
Company Expands Proprietary Pipeline to Include Long-Acting Versions of Two
|||Quarterly revenues of $44.2 million, driven by record manufacturing and royalty revenues from RISPERDAL® CONSTA®. Worldwide sales of RISPERDAL CONSTA by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., and Janssen-Cilag (Janssen) were approximately $399 million, growing 18.1% on an operational basis year-over-year. U.S. sales growth for the quarter ended December 31, 2009, was 13.7%, reflecting increased share and market growth while sales outside the U.S. were up 20.6% operationally.|
|||Net sales of VIVITROL® of $5.5 million, growing 17.4% over the prior quarter.|
|||GAAP net loss of $6.8 million and pro forma net income of $0.1 million.|
|||Strong financial position with cash and total investments of $357.5 million.|
|||Alkermes announced a novel, proprietary LinkeRx technology platform that enables the creation of injectable extended-release versions of antipsychotics and other CNS therapies. The companys lead candidate that leverages this platform, designated as ALKS 9070, is a once-monthly, injectable, extended-release version of aripiprazole, commercially available under the name ABILIFY®, for the treatment of schizophrenia.|
|||Positive data reported for phase 3 study of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. XR-NTX, marketed by Alkermes as VIVITROL, is an opioid antagonist administered once-monthly by|
Page 1 of 7
The following information was filed by Alkermes Inc on Thursday, February 4, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Alkermes Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alkermes Inc.